SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Unicycive Therapeutics, Inc. (UNCY) has a negative trailing P/E of -39.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 0.9 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -2.52%, forward earnings yield 116.28%. PEG 0.20 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (0/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -39.7); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -2.52%).
- Forward P/E 0.9 — analysts expect a return to profitability with estimated EPS of $8.07 for FY2027.
- PEG Ratio 0.20 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -2.52% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 116.28% as earnings recover.
Overall SharesGrow Score: 43/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — UNCY
Valuation Multiples
P/E (TTM)-39.7
Forward P/E0.9
PEG Ratio0.20
Forward PEG0.20
P/B Ratio34.88
P/S Ratio0.00
EV/EBITDA-4.4
Per Share Data
EPS (TTM)$-0.17
Forward EPS (Est.)$8.07
Book Value / Share$0.19
Revenue / Share$0.00
FCF / Share$-0.20
Yields & Fair Value
Earnings Yield-2.52%
Forward Earnings Yield116.28%
Dividend Yield0.00%
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2018 |
-35.5 |
0.00 |
-32.93 |
0.00 |
- |
| 2019 |
-18.3 |
-0.20 |
-47.65 |
0.00 |
- |
| 2020 |
-30.4 |
0.75 |
-28.54 |
0.00 |
- |
| 2021 |
-2.4 |
0.00 |
1.46 |
0.00 |
- |
| 2022 |
-0.5 |
0.01 |
-17.45 |
8.55 |
- |
| 2023 |
-0.7 |
-0.10 |
-5.59 |
31.56 |
- |
| 2024 |
-1.4 |
0.00 |
7.16 |
0.00 |
2.06% |
| 2025 |
-34.5 |
0.49 |
30.36 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-0.14 |
$0.00 |
$-1.12M |
- |
| 2019 |
$-0.27 |
$0.00 |
$-2.3M |
- |
| 2020 |
$-0.16 |
$0.00 |
$-2.51M |
- |
| 2021 |
$-0.71 |
$0.00 |
$-10.63M |
- |
| 2022 |
$-1.20 |
$951K |
$-18.06M |
-1899.5% |
| 2023 |
$-1.28 |
$675K |
$-30.54M |
-4525% |
| 2024 |
$-0.06 |
$0.00 |
$-36.73M |
- |
| 2025 |
$-1.67 |
$0.00 |
$-26.56M |
- |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$0.06 |
$-0.12 – $0.41 |
$71.53M |
$20.01M – $527.77M |
5 |
| 2027 |
$8.55 |
$-0.68 – $19.64 |
$403M |
$74.48M – $912.77M |
4 |
| 2028 |
$11.65 |
$7.21 – $18.46 |
$697.49M |
$63.79M – $863.49M |
4 |
| 2029 |
$9.96 |
$-0.72 – $27.65 |
$614.31M |
$71.4M – $966.51M |
2 |
| 2030 |
$10.72 |
$-0.78 – $29.76 |
$668.2M |
$116.8M – $1.58B |
2 |
